A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan
Inclusion Criteria:
Exclusion Criteria:
Buenos Aires, Buenos Aires C1120AAC, Argentina
Caba, Buenos Aires C1429BWN, Argentina
Ciudad Autonoma de Bs As, Buenos Aires C1119ACN, Argentina
Ciudad Autonoma de Bs As, Buenos Aires C1430AAQ, Argentina
Caba, Buenos Aires F.D. C1425FVH, Argentina
Hostalets de Balenya, Catalonia 08550, Spain